

**Supplement table 1** Cox regression models of lymphocyte subsets in the training cohort.


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Univariate analysis | | | Multivariate analysis | | |
|  | β | HR(95%CI) | *P* value | β | HR(95%CI) | *P* value |
| ≤60 |  |  |  |  |  |  |
| CD4 | -0.002 | 0.998(0.997-0.999) | <0.001 |  |  |  |
| Lg CD4 | -3.369 | 0.034(0.008-0.147) | <0.001 | -2.534 | 0.079(0.012-0.547) | 0.010 |
| CD8 | -0.001 | 0.999(0.998-1.000) | 0.085 |  |  |  |
| Lg CD8 | -1.221 | 0.295(0.093-0.932) | 0.038 | 0.089 | 1.093(0.300-3.983) | 0.893 |
| CD19 | -0.005 | 0.995(0.993-0.998) | <0.001 |  |  |  |
| Lg CD19 | -1.643 | 0.193(0.097-0.385) | <0.001 | -1.056 | 0.348(0.138-0.877) | 0.025 |
| >60 |  |  |  |  |  |  |
| CD4 | -0.002 | 0.998(0.997-0.999) | <0.001 |  |  |  |
| Lg CD4 | -3.006 | 0.049(0.016-0.151) | <0.001 | -2.847 | 0.058(0.012-0.291) | 0.001 |
| CD8 | -0.001 | 0.999(0.998-1.000) | 0.045 |  |  |  |
| Lg CD8 | -1.431 | 0.239(0.086-0.662) | 0.006 | -0.253 | 0.776(0.248-2.429) | 0.663 |
| CD19 | -0.003 | 0.997(0.994-0.999) | 0.008 |  |  |  |
| Lg CD19 | -1.190 | 0.304(0.132-0.701) | 0.005 | 0.002 | 1.002(0.348-2.889) | 0.996 |




**Supplement figure 1 A-B:** Survival curve subgroup analyses of patients. (A) Training cohort. (B) Validation cohort.



**Supplement figure 2** **A-B T-ROC curve of GSII, CD4, CD8, CD19 lymphocyte count among total patients.** (A) Training cohort. (B) Validation cohort.



**Supplement figure 3** (A-B)Concordance Index for nomograms ≤60 and >60 in training cohort. (C-D) Concordance Index for nomograms ≤60 and >60 in validation cohort. (E-F) T-ROC curve of≤60 and >60 in validation cohort.



**Supplement figure 4 Calibration plots for the nomogram.** (A-B) Calibration plots for 3 and 5 years of ≤60 in training cohort. (C-D) Calibration plots for 3 and 5 years of >60 in training cohort. (E-F) Calibration plots for 3 and 5 years of ≤60 in validation cohort. (G-H) Calibration plots for 3 and 5 years of >60 in validation cohort.



**Supplement figure 5** (A-B)Decision curves for training cohorts ≤60 and >60. (C-D) Decision curves for validation cohorts ≤60 and >60.

